Christina Hale: A man named Mohammed whom everyone should meet
Statewide, the evidence is all too clear: Our population and talent pool continue to decrease over time.
Statewide, the evidence is all too clear: Our population and talent pool continue to decrease over time.
The Greenfield-based animal health unit has posted more than a half-billion dollars in losses in the past three years, and it will face huge new corporate expenses as it goes its separate way after more than a half-century as part of Eli Lilly and Co.
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
The university said it has hired 33 research faculty to help under the “Grand Challenges” program in precision health, an initiative it rolled out two years ago.
The drug, launched in 2014, is one of Lilly’s fastest-growing medicines, but its fate could hinge on the results of another clinical trial for heart benefits. The Indianapolis-based drugmaker plans to release results later this year.
The larger 1951 photo shows the 4-H Club Parade at the fairgrounds’ coliseum, while the inset photo shows Eli Lilly showing a cow at the 1941 fair.
Indiana Utility Consumer Counselor Bill Fine is tasked with making sure Hoosier households and business aren’t overcharged for electricity, natural gas, water or wastewater.
Civic leaders breathed a sigh of relief on July 24 when Eli Lilly and Co. announced it planned to spin off its Greenfield-based animal-health unit, Elanco, in an initial public offering rather than selling it outright. Indianapolis-based Lilly had announced last October that it was exploring strategic options for the business. It’s a phrase that […]
While the California Consumer Privacy Act of 2018 targets the protection of personal information of California residents only, the law will have far greater impact in two material ways.
The run-up in share price seems to reflect investor sentiment that the Indianapolis drugmaker has turned a corner after more than a decade of struggling to launch new medicines.
The Indianapolis-based pharmaceutical company said the division’s headquarters would remain in Greenfield after the spinoff and that no job cuts are planned.
Forty years after starting an ad agency bearing his name, Tom Hirons is letting go of the steering wheel.
Indianapolis Power & Light has agreed not to raise the fixed monthly rate it charges most of its residential customers, under a rate-case settlement it reached with the Indiana Office of Utility Consumer Counselor and other stakeholders.
As the organization’s leaders plan for the next two decades, they’re targeting the 3.3 miles of the White River that runs through their property for new experiences and attractions.
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
The Lilly Endowment approved 1,062 grants in 2017 for a total of $537.8 million to 788 grantees.
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
The tension between a desire for investment and an inherent distrust of it is occurring across disadvantaged Indianapolis neighborhoods.